Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Acrivon Therapeutics, Inc. Common Stock (ACRV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ACRV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.33
1 Year Target Price $11.33
| 4 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.27% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.02M USD | Price to earnings Ratio - | 1Y Target Price 11.33 |
Price to earnings Ratio - | 1Y Target Price 11.33 | ||
Volume (30-day avg) 9 | Beta 1.56 | 52 Weeks Range 1.05 - 10.16 | Updated Date 07/10/2025 |
52 Weeks Range 1.05 - 10.16 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.24% | Return on Equity (TTM) -62.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -104104817 | Price to Sales(TTM) - |
Enterprise Value -104104817 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31355400 | Shares Floating 16676349 |
Shares Outstanding 31355400 | Shares Floating 16676349 | ||
Percent Insiders 20.78 | Percent Institutions 55.04 |
Upturn AI SWOT
Acrivon Therapeutics, Inc. Common Stock
Company Overview
History and Background
Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers where conventional therapies have limited effectiveness. Founded to address unmet needs in oncology, Acrivon is pioneering a unique patient selection approach using its proprietary OncoSignature platform.
Core Business Areas
- Drug Development: Discovery, development, and commercialization of oncology therapeutics using Acrivon's OncoSignature platform.
- OncoSignature Platform: Proprietary platform for patient selection based on predicting drug response, aiming to improve clinical trial outcomes and personalize cancer treatment.
Leadership and Structure
Dr. Peter Garland serves as the Chief Executive Officer. The company has a typical biotech organizational structure, with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- ACR-368: Acrivon's lead product candidate, a Chk1/2 inhibitor, is being developed for advanced solid tumors with specific genomic alterations. It's currently in clinical trials. No current market share as no product is commercialized, it's in clinical development. Competitors include companies developing similar Chk1/2 inhibitors and therapies for the target cancer types.
Market Dynamics
Industry Overview
The oncology market is highly competitive and rapidly evolving, with significant unmet needs and opportunities for targeted therapies and personalized medicine.
Positioning
Acrivon is positioned as a precision oncology company leveraging its OncoSignature platform to identify patients most likely to benefit from its therapies, differentiating it from traditional 'one-size-fits-all' approaches.
Total Addressable Market (TAM)
The global oncology drug market is projected to reach hundreds of billions of dollars. Acrivon's TAM depends on the specific cancers targeted by its therapies and the success of its patient selection strategy. Their TAM is based on the specific alterations they test for.
Upturn SWOT Analysis
Strengths
- Proprietary OncoSignature platform
- Targeted patient selection strategy
- Experienced leadership team
- Potential for personalized medicine in oncology
Weaknesses
- Dependence on clinical trial success
- High research and development costs
- Limited number of pipeline products
- No commercialized product yet
Opportunities
- Expansion of OncoSignature platform to other cancers
- Partnerships with pharmaceutical companies
- Potential for breakthrough therapy designation
- Acquisition of new technologies or assets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- AVXL
- GTHX
Competitive Landscape
Acrivon's competitive advantage lies in its OncoSignature platform, which aims to improve patient selection and clinical trial outcomes. It faces competition from larger pharmaceutical companies with established oncology portfolios and companies developing similar targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Acrivon's historical growth is measured by progress in its clinical trials and development of the OncoSignature platform.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its drug candidates. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include advancing ACR-368 through clinical trials and expanding the OncoSignature platform.
Summary
Acrivon Therapeutics is a clinical-stage biopharmaceutical company with a focus on precision oncology. Its unique OncoSignature platform could differentiate it, though it's subject to clinical trial and regulatory risks. Its financial health depends on continued funding and progress in clinical trials. The company has a potential to lead to Personalized medicine for cancer patients. Investors should be mindful of risks associated with clinical-stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
- Yahoo Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary across different sources. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://acrivon.com |
Full time employees 75 | Website https://acrivon.com | ||
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.